Actinium Pharmaceuticals, Inc. - FORM 10-Q - EX-32.2 - CERTIFICATION - August 4, 2017

Attached files

file filename
EX-10.5 - AMENDED AND RESTATED AT-THE-MARKET MARKET ISSUANCE SALES AGREEMENT, DATED JULY 3 - Actinium Pharmaceuticals, Inc.f10q0617ex10v_actinium.htm
EX-10.4 - OFFER LETTER; DATED MAY 26, 2017, BY AND BETWEEN ACTINIUM PHARMACEUTICALS, INC. - Actinium Pharmaceuticals, Inc.f10q0617ex10iv_actinium.htm
EX-10.8 - SEPARATION AND SETTLEMENT AGREEMENT, DATED MAY 12, 2017, BY AND BETWEEN ACTINIUM - Actinium Pharmaceuticals, Inc.f10q0617ex10viii_actinium.htm
EX-32.1 - CERTIFICATION - Actinium Pharmaceuticals, Inc.f10q0617ex32i_actiniumpharm.htm
EX-31.2 - CERTIFICATION - Actinium Pharmaceuticals, Inc.f10q0617ex31ii_actiniumpharm.htm
EX-31.1 - CERTIFICATION - Actinium Pharmaceuticals, Inc.f10q0617ex31i_actiniumpharm.htm
EX-10.9 - SEPARATION AND SETTLEMENT AGREEMENT, DATED MAY 12, 2017, BY AND BETWEEN ACTINIUM - Actinium Pharmaceuticals, Inc.f10q0617ex10ix_actinium.htm
EX-10.7 - CONSULTING AGREEMENT, DATED MAY 22, 2017, BY AND BETWEEN ACTINIUM PHARMACEUTICAL - Actinium Pharmaceuticals, Inc.f10q0617ex10vii_actinium.htm
EX-10.6 - AGREEMENT, DATED JUNE 6, 2017, BY AND BETWEEN ACTINIUM PHARMACEUTICALS, INC. AND - Actinium Pharmaceuticals, Inc.f10q0617ex10vi_actinium.htm
EX-10.3 - AMENDED AND RESTATED LICENSE AGREEMENT, DATED JUNE 8, 2017, BETWEEN ACTINIUM PHA - Actinium Pharmaceuticals, Inc.f10q0617ex10iii_actinium.htm
EX-10.1 - ASSIGNMENT AND CONSENT AGREEMENT, DATED JUNE 6, 2017, AMONG 275 MADISON AVENUE R - Actinium Pharmaceuticals, Inc.f10q0617ex10i_actinium.htm
10-Q - QUARTERLY REPORT - Actinium Pharmaceuticals, Inc.f10q0617_actiniumpharma.htm

Exhibit 32.2

  

CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Actinium Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steve O’Loughlin, Vice President, Finance and Corporate Development of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
   
2. The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: August 4, 2017 By: /s/ Steve O’Loughlin
    Steve O’Loughlin
    Vice President, Finance and Corporate Development
    (Duly Authorized Officer and Principal Financial and Accounting Officer)

 

Actinium Pharmaceuticals, Inc. Reports